Loading...
Please wait, while we are loading the content...
Similar Documents
Roche ’ s investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
| Content Provider | Semantic Scholar |
|---|---|
| Copyright Year | 2018 |
| Abstract | Basel, 21 October 2018 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA-372-001 trials that showed the investigational personalised medicine entrectinib shrank tumours (objective response rate; ORR) in more than half (57.4%) of people with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive solid tumours. Objective responses to entrectinib were seen across ten different solid tumour types (median duration of response [DOR]=10.4 months), including in people with and without central nervous system (CNS) metastases at baseline. [1] Importantly, entrectinib shrank tumours that had spread to the brain in over half of people (intracranial response; IC ORR=54.5%), with more than a quarter of these people having a complete response. [1] The safety profile of entrectinib was consistent with that seen in previous analyses.[1] |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://www.roche.com/dam/jcr:4485b997-46f5-47ab-a908-79ca386eb8f1/en/20181021-MR-Entrectinib_EN.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
